Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 119

1.

Controlling CRISPR-Cas9 Gene Editing.

Dowdy SF.

N Engl J Med. 2019 Jul 18;381(3):289-290. doi: 10.1056/NEJMcibr1906886. No abstract available.

PMID:
31314976
2.

GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics.

Springer AD, Dowdy SF.

Nucleic Acid Ther. 2018 Jun;28(3):109-118. doi: 10.1089/nat.2018.0736. Epub 2018 May 24. Review.

3.

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Dowdy SF, Levy M.

Nucleic Acid Ther. 2018 Jun;28(3):107-108. doi: 10.1089/nat.2018.29001.dow. Epub 2018 May 21. No abstract available.

PMID:
29782220
4.

Induction of RNAi Responses by Short Left-Handed Hairpin RNAi Triggers.

Hagopian JC, Hamil AS, van den Berg A, Meade BR, Eguchi A, Palm-Apergi C, Dowdy SF.

Nucleic Acid Ther. 2017 Oct;27(5):260-271. doi: 10.1089/nat.2017.0686. Epub 2017 Sep 21.

5.

Enhanced generation of iPSCs from older adult human cells by a synthetic five-factor self-replicative RNA.

Yoshioka N, Dowdy SF.

PLoS One. 2017 Jul 27;12(7):e0182018. doi: 10.1371/journal.pone.0182018. eCollection 2017.

6.

RNAi prodrugs targeting Plk1 induce specific gene silencing in primary cells from pediatric T-acute lymphoblastic leukemia patients.

Kolosenko I, Edsbäcker E, Björklund AC, Hamil AS, Goroshchuk O, Grandér D, Dowdy SF, Palm-Apergi C.

J Control Release. 2017 Sep 10;261:199-206. doi: 10.1016/j.jconrel.2017.07.002. Epub 2017 Jul 3.

PMID:
28684168
7.

Overcoming cellular barriers for RNA therapeutics.

Dowdy SF.

Nat Biotechnol. 2017 Mar;35(3):222-229. doi: 10.1038/nbt.3802. Epub 2017 Feb 27. Review.

PMID:
28244992
8.

Enhancing Endosomal Escape for Intracellular Delivery of Macromolecular Biologic Therapeutics.

Lönn P, Kacsinta AD, Cui XS, Hamil AS, Kaulich M, Gogoi K, Dowdy SF.

Sci Rep. 2016 Sep 8;6:32301. doi: 10.1038/srep32301.

9.

53BP1 and USP28 mediate p53 activation and G1 arrest after centrosome loss or extended mitotic duration.

Meitinger F, Anzola JV, Kaulich M, Richardson A, Stender JD, Benner C, Glass CK, Dowdy SF, Desai A, Shiau AK, Oegema K.

J Cell Biol. 2016 Jul 18;214(2):155-66. doi: 10.1083/jcb.201604081.

10.

Voices of biotech.

Amit I, Baker D, Barker R, Berger B, Bertozzi C, Bhatia S, Biffi A, Demichelis F, Doudna J, Dowdy SF, Endy D, Helmstaedter M, Junca H, June C, Kamb S, Khvorova A, Kim DH, Kim JS, Krishnan Y, Lakadamyali M, Lappalainen T, Lewin S, Liao J, Loman N, Lundberg E, Lynd L, Martin C, Mellman I, Miyawaki A, Mummery C, Nelson K, Paz J, Peralta-Yahya P, Picotti P, Polyak K, Prather K, Qin J, Quake S, Regev A, Rogers JA, Shetty R, Sommer M, Stevens M, Stolovitzky G, Takahashi M, Tang F, Teichmann S, Torres-Padilla ME, Tripathi L, Vemula P, Verdine G, Vollmer F, Wang J, Ying JY, Zhang F, Zhang T.

Nat Biotechnol. 2016 Mar;34(3):270-5. doi: 10.1038/nbt.3502. No abstract available.

PMID:
26963549
11.

Protein kinase Cζ exhibits constitutive phosphorylation and phosphatidylinositol-3,4,5-triphosphate-independent regulation.

Tobias IS, Kaulich M, Kim PK, Simon N, Jacinto E, Dowdy SF, King CC, Newton AC.

Biochem J. 2016 Feb 15;473(4):509-23. doi: 10.1042/BJ20151013. Epub 2015 Dec 3.

12.

Current views on inducing synthetic lethal RNAi responses in the treatment of cancer.

Kacsinta AD, Dowdy SF.

Expert Opin Biol Ther. 2016;16(2):161-72. doi: 10.1517/14712598.2016.1110141. Epub 2015 Dec 2. Review.

PMID:
26630128
13.

Combining CRISPR/Cas9 and rAAV Templates for Efficient Gene Editing.

Kaulich M, Dowdy SF.

Nucleic Acid Ther. 2015 Dec;25(6):287-96. doi: 10.1089/nat.2015.0545. Epub 2015 Nov 5. Review.

14.

Synthesis and Conjugation of Small Interfering Ribonucleic Neutral SiRNNs.

Hamil AS, Dowdy SF.

Methods Mol Biol. 2016;1364:1-9. doi: 10.1007/978-1-4939-3112-5_1.

15.

Cationic PTD/CPP-mediated macromolecular delivery: charging into the cell.

Lönn P, Dowdy SF.

Expert Opin Drug Deliv. 2015;12(10):1627-36. doi: 10.1517/17425247.2015.1046431. Epub 2015 May 20. Review.

PMID:
25994800
16.

Efficient CRISPR-rAAV engineering of endogenous genes to study protein function by allele-specific RNAi.

Kaulich M, Lee YJ, Lönn P, Springer AD, Meade BR, Dowdy SF.

Nucleic Acids Res. 2015 Apr 20;43(7):e45. doi: 10.1093/nar/gku1403. Epub 2015 Jan 13.

17.

Cellular activity of siRNA oligonucleotides containing synthetic isomorphic nucleoside surrogates.

Shin D, Lönn P, Dowdy SF, Tor Y.

Chem Commun (Camb). 2015 Jan 31;51(9):1662-5. doi: 10.1039/c4cc08809c.

18.

Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications.

Meade BR, Gogoi K, Hamil AS, Palm-Apergi C, van den Berg A, Hagopian JC, Springer AD, Eguchi A, Kacsinta AD, Dowdy CF, Presente A, Lönn P, Kaulich M, Yoshioka N, Gros E, Cui XS, Dowdy SF.

Nat Biotechnol. 2014 Dec;32(12):1256-61. doi: 10.1038/nbt.3078. Epub 2014 Nov 17.

20.

Ubiquitin-conjugating enzyme Ubc13 controls breast cancer metastasis through a TAK1-p38 MAP kinase cascade.

Wu X, Zhang W, Font-Burgada J, Palmer T, Hamil AS, Biswas SK, Poidinger M, Borcherding N, Xie Q, Ellies LG, Lytle NK, Wu LW, Fox RG, Yang J, Dowdy SF, Reya T, Karin M.

Proc Natl Acad Sci U S A. 2014 Sep 23;111(38):13870-5. doi: 10.1073/pnas.1414358111. Epub 2014 Sep 4.

Supplemental Content

Loading ...
Support Center